Stefano Cafarotti
Overview
Explore the profile of Stefano Cafarotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Werner R, Curioni-Fontecedro A, Mauti L, Addeo A, Peters S, Frauenfelder T, et al.
J Thorac Oncol
. 2024 Mar;
19(3):385-394.
PMID: 38453327
No abstract available.
2.
Cekani E, Martorell C, Martucci F, Patella M, Cafarotti S, Valenti A, et al.
Swiss Med Wkly
. 2023 Sep;
153:40110.
PMID: 37769653
Background: The prognostic role of programmed death-ligand 1 (PD-L1) expression in patients with localised and locally advanced non-small cell lung cancer has not been fully elucidated. This information could help...
3.
Cafarotti S, Torre T, Patella M, Demertzis S
Eur J Cardiothorac Surg
. 2023 Feb;
63(4).
PMID: 36852845
Treatment of malignant epithelial thymic tumours, including thymoma and thymic carcinoma, is based on surgical resection, whenever possible. Mainstay of surgical treatment is complete resection with clear margins. This may...
4.
Previsdomini M, Colombo J, Cerutti B, Gerber B, Hofmann A, Chiesa A, et al.
Swiss Med Wkly
. 2022 Jun;
152:w30184.
PMID: 35752954
Background: Patient blood management (PBM) promotes the routine detection and treatment of anaemia before surgery, optimising the management of bleeding disorders, thus minimising iatrogenic blood loss and pre-empting allogeneic blood...
5.
Minerva E, Tessitore A, Cafarotti S, Patella M
Front Surg
. 2022 May;
9:884048.
PMID: 35574541
Introduction: Rural populations in large countries often receive delayed or less effective diagnosis and treatment for lung cancer. Differences are related to population-based factors such as lower pro capita income...
6.
Patella M, Brunelli A, Adams L, Cafarotti S, Costardi L, De Leyn P, et al.
Semin Thorac Cardiovasc Surg
. 2022 Mar;
35(2):387-398.
PMID: 35272025
To investigate factors associated with the ability to receive adjuvant chemotherapy in patients with pathological N1 and N2 stage after anatomic lung resections for non-small cell lung cancer (NSCLC). Multicenter...
7.
Graff V, Gabutti L, Treglia G, Pascale M, Anselmi L, Cafarotti S, et al.
Braz J Anesthesiol
. 2021 Oct;
73(3):316-339.
PMID: 34627828
Background And Objectives: In this systematic review, we carried out an assessment of perioperative costs of local or regional anesthesia versus general anesthesia in the ambulatory setting. Methods: A systematic...
8.
Patella M, Minerva E, Porcellini I, Cianfarani A, Tessitore A, Cafarotti S
ANZ J Surg
. 2021 Aug;
91(10):2182-2187.
PMID: 34405522
Background: We described the results of surgical treatment of empyema, tracing outcomes throughout the passage from the open thoracotomy (OT) approach to video-assisted thoracoscopic surgery (VATS) in a single institute....
9.
Glatzer M, Leskow P, Caparrotti F, Elicin O, Furrer M, Gambazzi F, et al.
Transl Lung Cancer Res
. 2021 May;
10(4):1960-1968.
PMID: 34012806
Background: Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage...
10.
Saporito A, La Regina D, Perren A, Gabutti L, Anselmi L, Cafarotti S, et al.
Braz J Anesthesiol
. 2021 Apr;
73(3):243-249.
PMID: 33930345
Background And Objectives: Contribution margin per hour (CMH) has been proposed in healthcare systems to increase the profitability of operating suites. The aim of our study is to propose a...